Sign up to gain complete access to Medznat
Please verify that you are a Healthcare Professional. Register for complete access to all the content!
FDA clears new oral therapy rilzabrutinib for treatment-resistant...
FDA approves rilzabrutinib tablets as a new oral treatment option for adults with persistent or chronic ITP who show insufficient response to sta...
FDA expands access to omalizumab therapy with first interchangeab...
The FDA has authorized omalizumab-igec as the first interchangeable biosimilar to omalizumab for treating asthma, urticaria, chronic rhinosinusit...
FDA introduces front-of-package nutrition labels to tackle chroni...
The FDA has proposed requisition of front-of-package nutrition labels on most packaged foods to clearly display levels of saturated fat, sodium,...
EMA issues flu vaccine composition guidance for 2025/2026 season
EMA recommends updated trivalent influenza vaccines for the 2025/2026 season, selecting strains based on global surveillance data and excluding B...
Reddy’s and Henlius collaborate to commercialize daratumumab bios...
Dr. Reddy’s has secured exclusive U.S. and Europe commercialization rights for Henlius’s daratumumab biosimilar HLX15 in a deal worth...
Dr. Reddy’s and Bio-Thera forge strategic alliance to expand bios...
Dr. Reddy’s and Bio-Thera Solutions have entered into exclusive commercialization and license agreements for two proposed biosimilars&mdash...
Sanofi and Dr. Reddy’s partner to introduce RSV protection for pe...
Dr. Reddy’s Laboratories has entered into an exclusive agreement with Sanofi to promote and distribute nirsevimab in India—a single-d...
New FDA-approved medication for hemophilia offers dosing every 2...
Fitusiran, a groundbreaking treatment for hemophilia A and B is approved by the FDA, offering a less frequent dosing schedule of once every 2 mon...
FDA greenlights dupilumab for adolescents and adults with chronic...
Dupilumab has received FDA approval for chronic spontaneous urticaria in patients aged 12 years and older, expanding its use to over 300,000 U.S....
Fresh from the FDA: First-ever non-opioid for acute pain is now O...
Suzetrigine is a crucial non-opioid alternative for managing acute pain, helping to reduce reliance on opioids while ensuring effective patient r...
Pioneering antidiabetic leads as first FDA-approved therapy for o...
Tirzepatide improves sleep quality, promotes weight loss, and overall health in overweight people with obstructive sleep apnea.
Russia’s N protein-based vaccine emerges as strong contender in g...
N protein-based COVID-19 vaccine shows 85.2% efficacy and a strong safety profile, offering a crucial alternative for patients struggling with tr...
This website uses cookies to help us give you the best experience when you visit.
By using this website you consent to our use of cookies. For more information please review our cookie policy.
